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In this study, we show that iron depletion in Candida albicans with bathophenanthrolene disulfonic acid and
ferrozine as chelators enhanced its sensitivity to several drugs, including the most common antifungal,
fluconazole (FLC). Several other species of Candida also displayed increased sensitivity to FLC because of iron
restriction. Iron uptake mutations, namely, ftr1 and ftr2, as well as the copper transporter mutation ccc2,
which affects high-affinity iron uptake in Candida, produced increased sensitivity to FLC compared to that of
the wild type. The effect of iron depletion on drug sensitivity appeared to be independent of the efflux pump
proteins Cdr1p and Cdr2p. We found that iron deprivation led to lowering of membrane ergosterol by 15 to
30%. Subsequently, fluorescence polarization measurements also revealed that iron-restricted Candida cells
displayed a 29 to 40% increase in membrane fluidity, resulting in enhanced passive diffusion of the drugs.
Northern blot assays revealed that the ERG11 gene was considerably down regulated in iron-deprived cells,
which might account for the lowered ergosterol content. Our results show a close relationship between cellular
iron and drug susceptibilities of C. albicans. Considering that multidrug resistance is a manifestation of
multifactorial phenomena, the influence of cellular iron on the drug susceptibilities of Candida suggests iron
as yet another novel determinant of multidrug resistance.
Iron plays a key role in providing natural resistance to in-
fections in humans (5). Interestingly, recent studies suggest
that there could be a correlation between intracellular iron
concentration and the multidrug resistance (MDR) phenome-
non in mammalian cells (14). Iron depletion in mammalian
cells with iron chelators is known to activate hypoxia-inducible
factor 1 (HIF-1) (6–9, 31). Cellular iron status-dependent ac-
tivation of HIF-1 results in the activation of its target gene,
MDR1 (7). Ambient hypoxia also causes resistance to chemo-
therapy by the induction of human MDR1 in growing tumors
via activation of HIF-1 (7–9, 31).
Recent studies of the role of iron in recurrent vulvovaginal
candidosis have revealed that this element is important not
only for the normal function of host immunity but also for
pathogenic Candida owing to the fact that absence of this
metal resulted in reduced virulence and hence reduced yeast
invasion of the host epithelium (40). Availability of iron has
been found to play a critical role in different clinical infections,
and this represents a challenge to investigate the role of iron
more closely (5). Kuipers et al. (25–27) have shown that lac-
toferrin, an iron-binding glycoprotein, is synergistic with anti-
fungals against different Candida species. However, the effect
of iron on the drug susceptibility of Candida cells has yet to be
demonstrated experimentally.
Iron is usually present in its ferric form complexed to envi-
ronmental ligands (3, 5, 11, 21, 23). The insoluble ferric form
cannot be taken up by Candida directly and has to be first
solubilized by conversion to the ferrous form by the cell surface
ferric reductase encoded by CaCFL1 (3, 11, 18, 21). In abun-
dance, ferrous iron is taken up by an iron uptake system com-
prising the iron transporter FTR2. In contrast, when the avail-
ability of iron is low in the environment, Candida uses the
high-affinity iron uptake system, which comprises a membrane
permease (encoded by CaFTR1) (36) and a multicopper oxi-
dase (encoded by CaFET3) (12, 13). Since CaFET3 has an
essential requirement for copper (13, 42), reductive iron up-
take in Candida also depends on copper availability, which is
mediated by the intracellular copper transporter encoded by
CCC2 (23). An additional mechanism for iron uptake, a sid-
erophore transporter (encoded by SIT1) also exists in Candida,
which makes use of the low-molecular-mass organic molecule
siderophore to bind extracellular iron (20, 22).
The focus of this study was to find out whether the avail-
ability of iron could have an impact on the susceptibility of
Candida to antifungal drugs. We observed that iron depriva-
tion is a mechanism by which to enhance drug susceptibility in
Candida cells. Our results suggest that iron depletion further
introduces an increase in membrane fluidity, which in turn
leads to enhanced passive diffusion of drugs, thereby resulting
in enhanced drug susceptibility. We could also link changes in
membrane fluidity to lowered ergosterol levels found in iron-
deprived Candida cells probably because of down regulation of
ERG11.
* Corresponding author. Mailing address for Chinmay K. Mukho-
padhyay: Special Centre for Molecular Medicine, Jawaharlal Nehru
University, New Mehrauli Road, New Delhi 110067, India. Phone:
91-11-26704509. Fax: 91-11-26717081. E-mail: mukhopc@yahoo.com.
Mailing address for Rajendra Prasad: School of Life Sciences,
Jawaharlal Nehru University, New Mehrauli Road, New Delhi 110067,
India. Phone: 91-11-26704509. Fax: 91-11-26717081. E-mail: rp47
@hotmail.com.
† T.P. and A.C. contributed equally to this work.
 Published ahead of print on 5 September 2006.
3597
MATERIALS AND METHODS
Materials. Medium chemicals were obtained from HiMedia (Mumbai, India)
and Difco (Detroit, Mich.). Rhodamine 6G (R6G), nystatin, cycloheximide,
anisomycin, bathophenanthrolene disulfonic acid (BPS), bathocuproiene disul-
fonate (BCS), ferrozine, ferrous ammonium sulfate (FAS), ferric chloride
(FeCl3), 2-deoxy-D-glucose (DOG), dinitrophenol (DNP), and 1,6-diphenyl-
1,3,5-hexatriene were obtained from Sigma Chemical Co. (St. Louis, MO). FLC
was kindly provided by Ranbaxy Laboratories, India. All of the chemicals used in
this study were of analytical grade.
Growth media. Strains were routinely grown in YPD broth (1% yeast extract,
2% peptone, 2% dextrose), which served as iron-sufficient medium (ISM). Two
percent (wt/vol) Bacto Agar (Difco, BD Biosciences, NJ) was added to YPD
broth to make solid medium. For Ura strains, uridine (Sisco Research Labo-
ratory, Mumbai, India) at a concentration of 100 g/ml was added to the growth
medium. Iron-poor medium (IPM) was prepared by adding 200 M BPS or 200
M ferrozine to YPD or otherwise as mentioned in the figure legends (see Fig.
1, 2, and 4). Copper was chelated from YPD by adding 500 M BCS. Iron-rich
medium was prepared by adding either 200 M FAS or 100 M FeCl3 to YPD.
Strains used. The Candida albicans strains and various Candida spp. used in
this study are listed in Table 1. All of the strains were stored in 15% (vol/vol)
glycerol stock at 80°C. Before each experiment, the cells were freshly revived
on YPD plates from this stock. For all of these studies, Candida cells were
maintained on YPD at 37°C. To begin with, all of the experiments were done
with iron-replete cells. Cells suffered iron stress only during the experiments.
Growth curve. Cells were resuspended to an optical density at 600 nm (OD600)
of 0.1 in YPD broth with or without BPS and were incubated in a shaking water
bath at 37°C. OD600 readings were taken at intervals of 1 h, and then a line graph
was plotted to show differences in growth.
Drug susceptibility tests. Drug susceptibilities were measured by both broth
microdilution and spot assays. MICs for the strains were determined by the broth
microdilution method as described previously (32, 33, 35). The following stock
solutions were used (the solvent used is given in parenthesis): FLC, 1 mg/ml
(water); cycloheximide, 20 mg/ml (water); anisomycin, 10 mg/ml (water); nysta-
tin, 10 mg/ml (water). The final drug concentrations used in this study are given
in the figure legends. Susceptibilities to various drugs were checked in YPD. In
order to have iron-limited conditions for the cells, BPS (a ferrous iron chelator)
or ferrozine (a ferrous iron chelator) was added at the concentrations indicated
in the figure legends to deplete the YPD of iron. Iron mutants were rescued by
addition of either 200 M FAS or 100 M FeCl3 to YPD containing FLC.
Drug diffusion and efflux assay. (i) Passive diffusion. Passive diffusion of the
fluorescent compound R6G was determined by a protocol described previously
(32, 33, 35). In a typical diffusion assay, done as described earlier (32, 33, 35), to
achieve de-energization of exponentially grown Candida cells for depletion of
intracellular ATP, cells were resuspended in de-energization buffer (phosphate-
buffered saline without glucose) with 5 mM DOG and 5 mM DNP at a cell
density of 108 ml1. R6G was then added to the de-energized cell suspension to
a final concentration of 10 M and incubated for 40 min, following which the
cells were rapidly centrifuged and the extracellular concentration of R6G in the
supernatant was determined spectrophotometrically at 527 nm.
(ii) R6G efflux. The functionality of Cdr1p was checked by assaying the energy-
dependent efflux of R6G, a known substrate of this drug extrusion pump. The
protocol of the efflux assay has been described in our earlier publications (24, 32,
33, 35).
Measurement of fluorescence polarization. Steady-state fluorescence polariza-
tion studies were done with Candida cells with the fluorescent probe 1,6-diphenyl-
1,3,5-hexatriene at excitation and emission wavelengths of 360 and 426 nm,
respectively (32, 33, 35).
Quantitation of ergosterol. Sterols were extracted by the alcoholic KOH
method and the percentage of ergosterol was calculated as described previously
(32, 33, 35). The extracted sterols indicated a four-peak spectral absorption
pattern produced by ergosterol and 24(28)-dehydroergosterol [24(28)-DHE]
contents. Both ergosterol and 24(28)-DHE absorb at 281.5 nm, whereas only
24(28)-DHE absorbs at 230 nm. Ergosterol content is determined by subtracting
the amount of 24(28)-DHE (calculated from the A230) from the total ergosterol-
plus-24(28)-DHE content (calculated from the A281.5). Ergosterol content was
calculated as a percentage of the wet weight of the cells with the following
equations: % ergosterol  % 24(28)-DHE  [(A281.5/290)  F]/pellet weight, %
24(28)-DHE  [(A230/518) F]/pellet weight, and % ergosterol [% ergosterol
% 24(28)-DHE]  % 24(28)-DHE, where F is the factor for dilution in petro-
leum ether and 290 and 518 are the E values (in percent per centimeter)
determined for crystalline ergosterol and 24(28)-DHE, respectively.
RNA isolation and hybridization. Northern blot analyses were carried out
essentially by standard protocols as described before (35, 38). Equal loading of
RNA was checked by rRNA bands. RNA was electrophoresed on a denaturing
formaldehyde gel (1.2%) and blotted and UV cross-linked onto Hybond-N
nylon (Amersham Biosciences) membranes. Membrane-bound RNA was stained
with methylene blue before hybridization to check rRNA bands for equal load-
ing. Relative intensities of ERG11 mRNA and ERG3 mRNA signals in Northern
hybridizations were quantitated by exposure of the hybridized membrane in a
Fuji FLA5000 phosphorimager. ERG11 and ERG3 probes were made by PCR
amplification with primers ERG11F (5-ATACATGAATTCTACTGCTGCTG
CCAAAGC-3), ERG11R (5-ATACATAAGCTTCCCAAATGATTTCTGCT
G-3), ERG3F (5-ATACATGAATTCTTCATTCTTTTCACCGATTG-3), and
ERG3R (5-ATACATAAGCTTATCATCTGGTCTTCTGTA-3).
TABLE 1. Strains used in this study
Strain Genotype Source or reference
C. albicans strains
CAF2-1 URA3/ura3::imm434 15
CAI4 ura3::imm434/ura3::imm434 15
C4-SHB1.1-sit1 ura3::imm434/ura3::imm434 sit1/sit1::hisG-URA3-hisG 20
ftr1 ura3::imm434/ura3::imm434 ftr1::hisG/ftr1::hisG 36
ftr2 ura3::imm434/ura3::imm434 ftr2::hisG/ftr2::hisG 36
ftr1 ftr2 ura3::imm434/ura3::imm434 ftr1::hisG/ftr1::hisG
ftr2::hisG/ftr2::hisG
36
ccc2 ura3::imm434/ura3::imm434 ccc2::hisG/ccc2::hisG 42
DSY449 URA3/ura3::imm434 cdr1::hisG/cdr1::hisG 39
DSY1025 ura3::imm434/ura3::imm434 cdr1::hisG/cdr1::hisG
cdr2::hisG/cdr2::hisG
39
DSY1024(II) ura3::imm434/ura3::imm434 cdr1::hisG/cdr1::hisG
cdr2::hisG/cdr2::hisG camdr1::hisG/camdr1::hisG
flu1::hisG/flu::hisG
29
Non-C. albicans strains
Candida krusei ATCCa 6258 Ranbaxy Laboratories, India
Candida tropicalis ATCC 750 Ranbaxy Laboratories, India
Candida parapsilosis ATCC 22019 Ranbaxy Laboratories, India
Candida kefyr ATCC 2512 Ranbaxy Laboratories, India
Candida dubliniensis ATCC 33 Ranbaxy Laboratories, India
Candida glabrata ATCC 90030 Ranbaxy Laboratories, India
a ATCC, American Type Culture Collection.
3598 PRASAD ET AL. ANTIMICROB. AGENTS CHEMOTHER.
RESULTS
Iron starvation makes C. albicans susceptible to FLC. It is
known that iron deprivation affects the growth of several or-
ganisms (3, 11, 21, 34). Therefore, we first assessed if the
growth of C. albicans cells is affected by BPS at the concentra-
tion used in this study. The inset in Fig. 1A illustrates that the
growth of CA14 was not affected when cells were grown in 200
M BPS. It should be pointed out that concentrations of BPS
higher than 200 M caused growth inhibition and hence were
not used. The chelation of Fe2 (ferrous) by BPS was con-
firmed by the assay for ferroxidase activity and was performed
as described elsewhere (12). The enzyme ferroxidase converts
Fe2 (ferrous) to Fe3 (ferric), and the remaining Fe2 (fer-
rous) complexes with ferrozine to give a purple color. The
reduced intensity of the color of the ferrozine-Fe2 (ferrous)
complex, as indicated by the decrease in absorbance at 570 nm,
implies less availability of Fe2 (ferrous). At 570 nm, the num-
ber of arbitrary units per 200 g protein of the ferrozine-Fe2
(ferrous) complex was 0.5 in untreated CAI4 cells, which was
reduced to 0.38 in BPS-treated cells. These results clearly
showed that BPS at 200 M was able to chelate iron in the
medium without affecting the growth of the cells.
Two independent methods, namely, broth microdilution and
spot assays, were used to find out whether iron depletion
causes any change in drug susceptibility of Candida cells. The
dose-ranging inhibition curve depicted in Fig. 1A confirmed
that even though the growth of BPS-treated and untreated
Candida cells in drug-free medium was comparable; however,
FIG. 1. (A) Determination of dose-ranging inhibition by broth microdilution assay of CAI4 with FLC at concentrations varying from 0.13 to
64 g/ml in the absence (}) or presence () of 200 M BPS. Growth of cells was evaluated both visually and by reading the A600 in a microplate
reader as described earlier (32, 33, 35). The inset shows the growth curve of CAI4 cells as a semilogarithmic plot of OD600 as a function of time
(in hours) in the absence (}) or presence () of 200 M BPS. (B) Drug resistance profile of CAI4 cells as determined by spot assay for FLC in
the absence or presence of 200 M BPS. For spot assays, 5-l volumes of fivefold serial dilutions of each yeast culture (A600, 0.1) were spotted
onto YPD plates in the absence (control) or presence of FLC (0.5 g/ml). Growth differences were evaluated with drug-free controls following
incubation of the plates for 48 h as described elsewhere (32, 33, 35). Growth was not affected by the presence of the solvents used for the drugs
(data not shown). (C) MICs of FLC for CAI4 cells in the absence or presence of BPS. The lowest drug concentration that gave 80% inhibition
of growth compared to the drug-free control was determined by broth microdilution assay and evaluated both visually and by reading the A600 in
a microtiter plate reader as described earlier (32, 33, 35). (D) Drug susceptibility tests for CAI4 cells by spot assay in the absence or presence of
200 M ferrozine. FLC was used at a concentration of 0.5 g/ml. (E) Spot assays of CAI4 cells in the absence or presence of 200 M BPS for
cycloheximide (300 g/ml), anisomycin (5 g/ml), and nystatin (10 g/ml). Growth differences were recorded as described above. Growth was not
affected by the presence of the solvents used for the drugs (data not shown).
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the cells growing in the presence of BPS were distinctly more
susceptible to FLC compared to those growing under iron-
sufficient conditions. Spot assay data in Fig. 1B revealed that
cells growing in the presence of BPS showed increased sensi-
tivity to FLC compared to that of those growing under iron-
sufficient conditions. Spot assays (Fig. 1B) also confirmed the
MIC results (Fig. 1C).
Iron depletion with other chelators also increases the drug
sensitivity of C. albicans cells to FLC. BPS has been used in
studies including all of the classical iron-copper biology exper-
iments (2, 4, 10, 30, 31). Our objective in this study was to find
out whether the drug susceptibility of Candida cells is also
affected when the cellular iron level is compromised by other
chelators. To validate the results obtained with BPS, we used
ferrozine (Fe2 chelator). Figure 1D reveals that ferrozine-
treated cells also showed increased susceptibility to FLC. Sim-
ilar results were obtained with another Fe3 chelator, desfer-
rioxamine (data not shown).
Iron deprivation enhances the susceptibility of C. albicans
cells to other drugs. To check if an increase in the susceptibility
of C. albicans due to iron deprivation is limited to FLC, we
performed spot assays with cycloheximide (300 g/ml), nysta-
tin (5 g/ml), and anisomycin (10 g/ml). We observed that
CAI4 cells under IPM conditions displayed enhanced suscep-
tibility to the other tested drugs as well (Fig. 1E). Thus, it is
apparent that iron depletion led to enhanced susceptibility of
C. albicans cells to a variety of drugs.
Iron depletion results in an increase in the drug sensitivity
of other Candida spp. Both MIC and spot tests were performed
for six different Candida species with FLC as a test drug under
ISM and IPM conditions (Fig. 2). On the basis of broth mi-
crodilution assay data depicted in Fig. 2A as dose-ranging
inhibition curves, it became apparent that, similar to C. albi-
cans, all of the non-C. albicans species became sensitive to FLC
under iron-deprived conditions. To reconfirm broth microdi-
lution assay results, the lowest FLC concentration that showed
a marked difference in growth between ISM and IPM media
was selected for each species and spot tests were performed.
The spot assay results depicted in Fig. 2C largely confirmed the
MIC results shown in Fig. 2B. The extent of sensitivity of
non-C. albicans species to FLC was variable for different spe-
cies and was in the following order: C. kefyr  C. glabrata  C.
tropicalis  C. krusei  C. dubliniensis  C. parapsilosis.
Candida mutants defective in iron and intracellular copper
transport show increased susceptibility to FLC. In order to
confirm the role of iron in the drug susceptibility of Candida
cells, we used different iron acquisition-defective Candida mu-
tants in the following experiment. All of the null mutants and
wild-type cells showed similar growth in YPD, but when their
growth was challenged with FLC in the spot assay, null mutants
defective in iron uptake, namely, ftr1 (defective in high-affin-
ity iron uptake) and ftr1 ftr2 (null mutant of both the high-
affinity iron transporters), showed increased susceptibility to
FLC in the complete absence of any iron chelator. Mutant
strain ftr2 (devoid of another iron transporter) only showed a
marginal increase in susceptibility, whereas sit1 (defective in
siderophore transport) showed no change in its sensitivity to
FLC (Fig. 3A). Interestingly, ccc2 cells (defective in copper
transport) also showed enhanced sensitivity to FLC in the
absence of any chelator (Fig. 3A). Of note here is that copper
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is an essential component of the multicopper oxidase (FET3)
responsible for high-affinity iron uptake. Chelation of copper
from the medium by BCS resulted in cells with increased sen-
sitivity to FLC (Fig. 3B). These results indicate that chelation
of copper, which affects high-affinity iron transport in Candida,
enhances the drug sensitivity of Candida cells even under iron-
rich medium conditions.
Supplementation of the medium with iron reverses the en-
hanced susceptibility of Candida to FLC. To confirm the iron
and copper chelation effects on the drug sensitivity of Candida
cells, we tested if supplementation of the medium with iron
salts could reverse the effect. For this, we used ftr1, ftr2,
ftr1 ftr2, and ccc2 mutant cells and assessed their suscep-
tibilities to FLC under iron-rich medium conditions. Figure 3A
shows that when these cells were grown in the presence of 200
M FAS or 100 M FeCl3, the inhibitory effect of FLC on
growth was reversed.
Synergism between iron depletion and sensitivity to FLC is
not dependent on multidrug efflux transporter activity. Over-
expression of drug efflux pumps is one of the well-known mech-
anisms for the development of FLC resistance in Candida (16,
19). To examine the role, if any, of major ABC efflux pumps,
namely, CDR1, CDR2, and MFS pump member CaMDR1, in
synergism with iron deprivation and drug sensitivity, we did an
experiment with efflux pump-encoding gene null mutants
DSY449 (cdr1), DSY1024II (cdr1 cdr2 camdr1 flu1),
and DSY1025 (cdr1 cdr2). Spot assays were done to inves-
tigate how the sensitivities of drug efflux pump mutants
DSY449 (cdr1), DSY1024II (cdr1 cdr2 camdr1 flu1),
and DSY1025 (cdr1 cdr2) were affected when they were
exposed to FLC under iron-limiting conditions. Both MIC and
spot test data clearly demonstrate that there was no difference
in sensitivity to FLC under ISM and IPM conditions between
null mutants and the wild type (Fig. 4A and B).
The involvement of drug efflux pumps in influencing the
drug sensitivity of Candida cells under IPM conditions was
further ruled out by examining and comparing R6G (a fluo-
rescent substrate of Cdr1p) efflux rates. In a typical experi-
ment, Candida cells grown under IPM and ISM conditions
were de-energized by exposure to DOG and DNP as described
in our previous publications (32, 33, 35). R6G was added to a
final concentration of 10 M to the de-energized cells resus-
pended in phosphate-buffered saline at a cell density 108 ml1
and incubated to attain steady intracellular accumulation. The
efflux of equilibrated fluorescent R6G was initiated by the
addition of 1 mole of glucose. The extracellular concentration
of R6G was monitored by measuring its A527. Our results show
that there was no difference in the extracellular concentration
of R6G between the cells grown under IPM and ISM condi-
tions (data not shown). This suggests that the efflux rates and
levels of R6G remained unchanged irrespective of the intra-
cellular iron status. Thus, any contribution of efflux pump
protein activity in enhancing the drug susceptibilities of Can-
dida cells upon iron deprivation was excluded from these ex-
periments.
Membrane ergosterol level is altered under iron-depleted
conditions. Recent microarray-based experiments suggested
that cellular iron regulates a host of genes, including those
involved in membrane homeostasis (28). We explored the ef-
fect of iron deprivation on membrane lipid composition, which
in turn may affect the ability of the drug to permeate the cell
membrane. In order to examine if iron affects the level of
ergosterol, one of the main constituents of the cell membrane,
we checked the ergosterol contents of iron-depleted cells and
iron mutant cells. There was a marked reduction in ergosterol
content in CAI4 cells under IPM conditions, which ranged
from 10% for BCS-treated cells to 32.5% for BPS-treated cells
(Table 2). Of note here is that the decrease in ergosterol levels
could be reversed by iron supplementation (data not shown).
Interestingly, iron mutant cells (ftr1 and ccc2) also showed
FIG. 3. (A) Drug resistance profiles of iron mutants as determined by spot assay in the absence (control) or presence of FLC (0.5 g/ml) and
reversal of FLC susceptibility by rescuing the growth defect of iron acquisition-defective mutant cells by addition of 200 M FAS or 100 M ferric
chloride to a YPD plate containing FLC. (B) Spot assay for untreated CAI4 cells and CAI4 cells treated with 500 M BCS in the absence (control)
or presence of FLC (0.5 g/ml).
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reduced ergosterol contents compared to wild-type cells (Table
2). No other major change in membrane lipids was observed
under IPM conditions (data not shown).
Iron starvation leads to a more fluid membrane. We had
earlier observed an intricate relationship between the (i) mem-
brane fluidity and lipid composition and (ii) drug susceptibility
of Candida cells (32, 33, 35). We had proposed that both entry
and extrusion of drugs may be affected if membrane lipids are
altered. In view of the reduction in ergosterol levels under IPM
conditions, this aspect was explored. We used steady-state flu-
orescence polarization (measured as a “p” value) to examine
the physical state of the membranes of cells grown under IPM
and iron-rich medium conditions. A decrease in the p value
implies a decrease in membrane order or an increase in mem-
brane fluidity. The CAI4 strain of C. albicans showed a re-
duced p value under iron depletion conditions and under cop-
per depletion conditions as well (Table 2). A direct link
between membrane fluidity and intracellular iron levels was
FIG. 4. (A) Drug susceptibilities of drug efflux pump mutants DSY449, DSY1025, and DSY1024(II) as determined by spot assays in the absence
or presence of 100 M BPS. To detect any effect of BPS on growth, a low concentration of FLC (0.125 g/ml), at which mutant cells could grow,
was used. (B) MICs of FLC for drug efflux pump mutants in the absence or presence of BPS are represented as histograms, and the OD600 of the
cells is plotted on the y axis. Clear bars represent cells grown without BPS, and shaded bars represent cells grown in the presence of 100 M BPS.
The lowest FLC concentration that gave 80% inhibition of growth compared to the drug-free control was 0.125 g/ml for all of the mutant cells
grown with or without BPS. (C) Northern blot analyses of ERG11 and ERG3. (a) ERG11 transcript level. (b) ERG3 transcript levels in strain CAI4
(lane 1), strain CAI4 grown in the presence of 200 M BPS (lane 2), strain ccc2 (lane 3), strain ftr1 (lane 4), strain ftr2 (lane 5), and strain
ftr1 ftr2 (lane 6). (c) Loading controls for verifying equal gel loading of total RNA.
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established when mutants defective in iron transport, viz.,
ftr1, and copper transport, viz., ccc2, were analyzed. These
mutant cells possessed increased membrane fluidity compared
to the wild-type strain (Table 2), which could be reversed by
addition of iron (data not shown).
Iron depletion leads to an increase in passive diffusion of
drugs. To test the effect of passive influx of the drug, we first
blocked the contribution of the efflux pumps by de-energizing
the cells in order to deplete the intracellular ATP. R6G diffu-
sion was then monitored in de-energized cells as described in
Materials and Methods. Table 2 depicts extracellular levels of
R6G in IPM compared to CAI4 cells grown under ISM con-
ditions. It is clear that depriving cells of either iron or copper
resulted in enhanced passive diffusion, as was evident from a
decreased extracellular concentration of R6G. The mutants
defective in high-affinity iron (ftr1) and copper (ccc2) trans-
port also showed enhanced membrane fluidity and diffusion of
R6G (Table 2). The enhanced passive diffusion under iron-
starved conditions could be reversed by addition of iron to the
medium (data not shown). Similarly, with ftr1 and ccc2 cells,
enhanced R6G diffusion could be brought back to normal
levels by supplementation of the medium with iron salts (data
not shown).
Ergosterol biosynthetic genes are regulated by iron. Recent
microarray data showed that among all of the ergosterol bio-
synthetic genes, iron deprivation results in down regulation of
ERG11 and up regulation of ERG3 (both genes are known to
have a reverse relationship) (28). Since we observed in our
study that iron deprivation leads to lowering of ergosterol
content, we wanted to correlate it with the transcript level of
these genes. To find out whether expression of any of these two
genes is affected by iron depletion, we checked ERG3 and
ERG11 transcript levels by Northern blot analyses with iron-
starved and iron acquisition-defective mutant strains of C. al-
bicans. We observed that iron deprivation led to the down
regulation of ERG11, which encodes lanosterol 14-	 demeth-
ylase, a key enzyme of ergosterol biosynthesis (Fig. 4C). North-
ern blot assays of iron-deprived cells, as well as of iron trans-
port-defective mutants (ftr1, ftr2, ftr1 ftr2, and ccc2),
showed considerable down regulation of ERG11 transcript.
ERG3 acts downstream of ERG11 in the ergosterol biosynthe-
sis pathway and encodes the 5,6-desaturase. In contrast to
ERG11, ERG3 was up regulated under IPM conditions (Fig.
4C). In an azole-inhibited pathway, Erg3p is responsible for
converting the nontoxic 14-methyl intermediates (1) which ac-
cumulate because of azole inhibition of lanosterol 14-	 de-
methylase into the toxic sterol 14-methylergosta-8,24(28)-dien-
3,6-diol. ERG3, being up regulated under iron-depleted
conditions, becomes synergistic with azoles because of greater
accumulation of the toxic intermediate.
DISCUSSION
Iron is an absolute requirement for most organisms and
assumes an important role in host innate immunity (5, 17, 40).
It has also been established that in Candida, tight regulatory
specialized iron acquisition tactics constitute virulence factors
(20, 36). However, the requirement of the high-affinity iron
permease for infection in a mouse model (36), the requirement
of a siderophore transporter for epithelial invasion, and the
iron-dependent endothelial injury caused by C. albicans have
established a role for iron in systemic infections (17). In the
present study, we explored if iron availability affects the drug
susceptibilities of Candida cells. For the first time, our results
demonstrate that alterations in the intracellular iron concen-
tration could also play a role in the defense mechanism of
Candida against drugs. We have demonstrated that deprivation
of iron results in increased sensitivity of C. albicans cells to a
host of drugs. Since all of the drugs tested have different
mechanisms of action, with varied targets within the cell, this
implies that iron starvation affects the cell in a broad manner.
Other non-C. albicans species of Candida tested, e.g., C. krusei,
C. tropicalis, C. dubliniensis, C. kefyr, C. parapsilosis, and C.
glabrata, also turned sensitive to drugs under iron-depleted
conditions, which confirmed that the effect of iron is not lim-
ited to a single Candida species and may represent another
mechanism of regulation of drug resistance in these opportu-
nistic fungi. There have been a few earlier reports suggesting
the possibility of a link between intracellular iron levels and
drug resistance. For example, lactoferrin, an iron-binding gly-
coprotein, was found to be synergistic with antifungals against
C. albicans, C. glabrata, and C. tropicalis (25–27).
The possibility of iron depletion resulting in a growth defect
in C. albicans cells and hence an increase in drug sensitivity was
ruled out. We alleviated such concerns by monitoring the
growth of CAI4 cells and demonstrated that while BPS was
sufficient to chelate iron at the concentration used in this study,
it did not affect the growth of the cells (Fig. 1A, inset). This was
further confirmed when we used various iron uptake mutants
(ftr1, ftr2, and double mutant ftr1 ftr2), as well as an
intracellular copper transporter mutant (ccc2). Interestingly,
all iron transport-defective mutants showed comparable
growth and were found to be inherently sensitive to FLC com-
pared to the wild type without iron chelation (Fig. 3A). How-
ever, sit1, a siderophore uptake mutant, did not show a sim-
ilar increase in susceptibility to FLC compared to wild-type
cells (Fig. 3A). This could be explained by the fact that since
both the high- and low-affinity iron uptake machinery of sit1
mutant cells is still intact, cells do not need to resort to sid-
erophore-mediated iron uptake to satisfy their needs. A direct
link between iron levels and drug resistance was further estab-
lished when the drug-sensitive phenotype was found to be
reversed upon supplementation of the growth medium with
TABLE 2. Ergosterol contents, p values, and passive diffusion of
R6G in untreated and BPS- and BCS-treated wild-type cells
and mutant cells with defective iron uptake
Strain (condition for
growth) % Ergosterol
a p valueb OD527c
CAI4 1.22 
 0.05 0.171 
 0.001 0.309 
 0.023
CAI4 (200 M BPS) 0.81 
 0.02 0.08 
 0.01 0.209 
 0.02
CAI4 (500 M BCS) 1.08 
 0.04 0.113 
 0.008 0.202 
 0.033
ftr1 0.97 
 0.02 0.103 
 0.01 0.237 
 0.019
ccc2 1.03 
 0.033 0.114 
 0.01 0.202 
 0.02
a The mean ergosterol content of cells is expressed as a percentage of the wet
weight of cells 
 the standard deviation of three sets of experiments (33).
b The mean p value of cells (inversely proportional to membrane fluidity) 

the standard deviation of three sets of experiments is shown (32, 33, 35).
c The mean OD527 of supernatant, for checking passive diffusion of R6G inside
cells (a lower OD implies a higher concentration of R6G inside the cells), 
 the
standard deviation of three sets of experiments is shown (32, 33, 35).
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extra iron salts (ferrous ammonium sulfate or ferric chloride)
(Fig. 3A). Taken together, our results confirmed that Candida
cells become relatively more sensitive to drugs when they are
deficient in iron, either because of chelation of the metal or
because of their iron acquisition defect mutations (ftr1, ftr2,
ftr1 ftr2, and ccc2).
Since overexpression of the drug efflux pump-encoding
genes is one of the predominant mechanisms responsible for
conferring a drug resistance phenotype on C. albicans, we first
hypothesized that the observed changes in drug susceptibility
due to iron deprivation could be the result of reduced drug
efflux. However, when we used various efflux pump null mu-
tants, viz., cdr1, cdr1 cdr2, and cdr1 cdr2 camdr1
flu1, and compared their sensitivities to FLC under IPM and
ISM conditions, none of the mutants showed any further in-
crease in sensitivity to FLC (Fig. 4A and B). This implies that
the synergism between antifungals and iron starvation is not
directly related to the activity of the efflux pump proteins. The
issue that iron levels exert their influence on drug susceptibil-
ities of Candida cells by an independent mechanism was finally
settled when we observed that the efflux of the fluorescent
substrate R6G mediated by the Cdr1p and Cdr2p efflux pro-
teins remained the same, irrespective of the iron levels in
Candida cells.
A recent genome-wide study of gene expression as a func-
tion of alterations in environmental concentrations of iron
revealed that a host of genes are highly expressed at low iron
concentrations while several transcripts are up regulated under
high-iron conditions (28). Among the iron-regulated genes,
cytochrome (ERG11, ERG3) and fatty acid metabolism
(OLE1) genes were also found to be affected by the iron status
of cells. Since we observed the ergosterol content of cells in
IPM to be lower than that of those grown under ISM condi-
tions, we hypothesized that changes in ERG genes under iron
deprivation conditions could affect ergosterol levels, which
could explain the higher membrane fluidity and enhanced pas-
sive drug entry observed. We observed that ERG11 was con-
siderably down regulated under iron-restricted conditions,
while ERG3 showed the opposite effect under similar condi-
tions. Interestingly, CAI4 cells grown in IPM showed a sub-
stantial reversible decrease in fluorescence anisotropy (p value
[membrane order]), implying that iron deprivation indeed re-
sults in ergosterol-dependent membrane fluidization. It was
further evident that iron deprivation fluidizes the membrane
when the iron uptake mutants ftr1, ftr2, and ftr1 ftr2 and
the intracellular copper transporter mutant ccc2 showed in-
herently lower ergosterol content and enhanced membrane
fluidity (data not shown). This increase in membrane fluidity
directly results in increased passive diffusion of drugs and sen-
sitization of Candida cells. The fact that CAI4 cells under iron
deprivation, iron acquisition-defective mutant ftr1, and intra-
cellular copper transporter mutant ccc2 showed increased
R6G passive diffusion and ERG11 gene down regulation sup-
ports our conclusions.
Taken together, our results demonstrate that iron depriva-
tion of Candida cells regulates ergosterol synthesis genes, re-
sulting in lower levels of this very important constituent of the
membrane. Ergosterol-depleted cellular membrane, in turn,
becomes more fluid, presumably allowing faster passive entry
of drugs and thus increasing the drug sensitivity of the cells. A
recent demonstration by Raymond’s group that Upc2p, a zinc
cluster factor that regulates ERG genes, also affects iron ac-
quisition genes, points to a close relationship between iron and
ergosterol metabolism in Candida (37). The possibility of co-
regulation of MDR, lipid biosynthesis, and iron acquisition
genes through common regulators also exists, as has already
been observed in several instances. On the one hand, PDR1
and PDR3, well-known Zn(II)-Cys6-Zn(II) transcription fac-
tors which regulate pleiotropic drug resistance in Saccharomy-
ces cerevisiae, target the sphingolipid biosynthetic gene IPT1,
and on the other hand, these key regulators also affect the
efflux and storage of cellular iron (41). In conclusion, changes
in the drug susceptibility of Candida due to iron represent a
well-regulated new defense mechanism that merits a closer
look.
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